EMDEX Limited is pleased to announce a new strategic partnership with Pharmécrit effective March 5, 2018.
This relationship is established with a sole objective of producing high quality, evidence-based, and up-to-date information about drugs and their therapeutic applications. This will be made available through EMDEX publications to all healthcare professionals in Nigeria, Africa, and the rest of the world.
Pharmέcrit, a medical communications company, is the new leading medical content contributor to EMDEX publications. The company will focus on working collaboratively with EMDEX Editor, Chris C. Obi to enhance the quality of medical information available to healthcare professionals.
EMDEX is Nigeria’s No.1 reference source of drug and therapeutic information for healthcare professionals, since 1991. The organization has since grown in its reach and publications and is now a proud publisher of EMDEX Mobile App – developed in partnership with ITmedicus.
Founder of EMDEX, Chris C. Obi believes that both companies have a great future ahead, which must be guided by the common passion for producing reliable drug information and other clinical decision support tools.
Pharmέcrit is a medical communications company providing medical writing solutions for clinicians, researchers, pharmaceutical/medical device companies, and other organizations such as academic institutions, health and wellness establishments, etc. Anuolu Bank-Oni, the principal medical writer and consultant of Pharmécrit, is a PharmD graduate with extensive experience in pharmacy practice and medical writing. She combines her therapeutic expertise with her ability to clearly and accurately convey complex scientific information to a target audience, such as patients, the general public, healthcare professionals, and regulators.
If you would like to know more about Pharmέcrit and its services, please visit www.pharmecrit.com or contact Anuolu Bank-Oni ([email protected])
If you are interested in EMDEX publications, please visit www.EmdexOnline.com or contact Chris C. Obi ([email protected]) for more information